Angiotensin-II Receptor Antibody Blockade With Losartan in Patients With Lupus Nephritis

Unknown Not Applicable NCT03526042

Study Description

Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma. They act by binding to the AT1 receptor and their effects can be blocked with the use of angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media thickness progression in patients with lupus nephritis compared to patients treated with enalapril.

Study Details

Registry ID:
NCT03526042
Conditions:
Atherosclerosis, Lupus Nephritis
Phase:
Not Applicable
Target Enrollment:
40 participants
Start Date:
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →